Promising areas of pharmacotherapy for obesity

• Main Authors: M. A. Druzhilov, T. Yu. Kuznetsova, G. A. Chumakova
• Format: Article
• Language: Russian
• Published: «FIRMA «SILICEA» LLC 2021-04-01
• Series: Российский кардиологический журнал
• Subjects: obesity; cardiorenometabolic risk; glucagon-like peptide-1 receptor agonists; gliflozins
• Online Access: https://russjcardiol.elpub.ru/jour/article/view/4279

The increasing prevalence of obesity, accompanied by an increase in the frequency of metabolic disorders, hypertension, associated conditions and diseases, dictates the need to optimize preventive and therapeutic strategies of the health care system, including pharmacological approaches to correcting obesity and the related risk. The evolution of this area led both to the disappearance of drugs that increase the risks of cardiovascular events, cancer, mental disorders or having other pronounced adverse effects, and to the emergence of unique drugs that not only lead to a decrease in body mass index, but also allow multifactorial effect on various components of adiposopathy or visceral obesity, among which glucagon-like peptide-1 receptor agonist liraglutide is currently registered with the indication for obesity. In this regard, the study continues in this regard and other representatives of this class, as well as drugs from sodium-glucose cotransporter-2 inhibitors group. Many other promising pharmacological agents are currently being studied, a review of which is presented in this article.